Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 440.40
-8.20 (-1.83%)
Aug 14, 2026, 5:29 PM CET
STO:SOBI Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 30,622 | 28,238 | 26,027 | 22,123 | 18,790 | 15,529 | |
Revenue Growth | 13.54% | 8.49% | 17.65% | 17.74% | 21.00% | 1.76% |
Cost of Revenue | 6,588 | 5,967 | 5,717 | 4,963 | 4,413 | 3,484 |
Gross Profit | 24,034 | 22,271 | 20,310 | 17,160 | 14,377 | 12,045 |
Selling, General & Admin | 11,020 | 10,973 | 10,967 | 9,773 | 7,637 | 6,294 |
Research & Development | 3,689 | 3,249 | 3,529 | 2,743 | 2,252 | 1,987 |
Other Operating Expenses | -25 | -9 | -9 | -9 | -32 | -30 |
Operating Expenses | 14,684 | 14,213 | 14,487 | 12,507 | 9,857 | 8,251 |
Operating Income | 9,350 | 8,058 | 5,823 | 4,653 | 4,520 | 3,794 |
Interest Expense | -701 | -802 | -1,239 | -1,111 | -458 | -419 |
Interest & Investment Income | 22 | 22 | 70 | 27 | 5 | - |
Earnings From Equity Investments | -27 | -3 | - | - | - | - |
Currency Exchange Gain (Loss) | -79 | -79 | 9 | -91 | -44 | 18 |
Other Non Operating Income (Expenses) | -27 | -26 | -59 | -49 | -27 | -35 |
EBT Excluding Unusual Items | 8,538 | 7,170 | 4,604 | 3,429 | 3,996 | 3,358 |
Merger & Restructuring Charges | -287 | -493 | -83 | -23 | -363 | - |
Gain (Loss) on Sale of Assets | - | - | -2 | -1 | - | -56 |
Asset Writedown | -7,115 | -6,643 | 15 | -65 | - | -7 |
Other Unusual Items | 102 | - | -127 | -385 | -312 | - |
Pretax Income | 1,238 | 34 | 4,407 | 2,955 | 3,321 | 3,295 |
Income Tax Expense | -145 | -442 | 528 | 546 | 683 | 616 |
Earnings From Continuing Operations | 1,383 | 476 | 3,879 | 2,409 | 2,638 | 2,679 |
Minority Interest in Earnings | -1 | 2 | 6 | - | - | - |
Net Income | 1,382 | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
Net Income to Common | 1,382 | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
Net Income Growth | -68.39% | -87.70% | 61.27% | -8.68% | -1.53% | -17.44% |
Shares Outstanding (Basic) | 345 | 344 | 342 | 323 | 296 | 295 |
Shares Outstanding (Diluted) | 349 | 348 | 346 | 326 | 298 | 297 |
Shares Change | 0.61% | 0.59% | 6.01% | 9.22% | 0.56% | -0.28% |
EPS (Basic) | 4.00 | 1.39 | 11.37 | 7.47 | 8.92 | 9.08 |
EPS (Diluted) | 3.96 | 1.37 | 11.24 | 7.39 | 8.84 | 9.03 |
EPS Growth | -68.61% | -87.81% | 52.10% | -16.39% | -2.11% | -17.16% |
Free Cash Flow | 7,834 | 8,525 | 7,218 | 3,597 | 4,504 | 5,423 |
Free Cash Flow Per Share | 22.45 | 24.52 | 20.89 | 11.04 | 15.09 | 18.27 |
Gross Margin | 78.49% | 78.87% | 78.03% | 77.57% | 76.51% | 77.56% |
Operating Margin | 30.53% | 28.54% | 22.37% | 21.03% | 24.05% | 24.43% |
Profit Margin | 4.51% | 1.69% | 14.93% | 10.89% | 14.04% | 17.25% |
Free Cash Flow Margin | 25.58% | 30.19% | 27.73% | 16.26% | 23.97% | 34.92% |
EBITDA | 12,414 | 11,362 | 9,282 | 7,537 | 6,593 | 5,604 |
EBITDA Margin | 40.54% | 40.24% | 35.66% | 34.07% | 35.09% | 36.09% |
D&A For EBITDA | 3,064 | 3,304 | 3,459 | 2,884 | 2,073 | 1,810 |
EBIT | 9,350 | 8,058 | 5,823 | 4,653 | 4,520 | 3,794 |
EBIT Margin | 30.53% | 28.54% | 22.37% | 21.03% | 24.05% | 24.43% |
Effective Tax Rate | - | - | 11.98% | 18.48% | 20.57% | 18.70% |